Actively Recruiting
Evaluating Safety and Early Effectiveness of Autologous Drug-Loaded Neutrophils NeuMed with Monomethyl Auristatin E in Adults Aged 18-70 with Unresectable Pancreatic Cancer
Led by The First Affiliated Hospital of Air Force Medicial University · Updated on 2025-09-30
3
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Autologous Drug-Loaded Neutrophils NeuMed carrying the drug Monomethyl Auristatin E MMAE to treat patients with Unresectable Pancreatic Cancer. This early phase 1, single-arm study aims to verify the safety and assess the anti-tumor effectiveness of this novel therapy in patients whose cancer cannot be removed by surgery. Participants will have their neutrophil cells collected and cultured in a GMP-compliant laboratory, where the cells are loaded with MMAE. Before reinfusion of these neutrophil biological agents, patients receive stereotactic radiotherapy at doses of 2-6 Gy targeted to pancreatic cancer lesions. The reinfused neutrophil dose ranges from 2.0 to 8.0 x 108 cells. During the 12-month study, participants will be monitored closely for safety and treatment effects. Researchers will assess anti-tumor response and record any adverse effects. Evaluations include clinical assessments and laboratory tests to check liver, kidney, and bone marrow function. The total participation period covers treatment and follow-up to understand the therapys safety and preliminary efficacy.
CONDITIONS
Brief Title
A Single-Arm Investigator-Initiated Tria (IIT) Evaluating the Safety and Preliminary Efficacy of Autologous Drug-Loaded Neutrophils (NeuMed) in Patients With Unresectable Pancreatic Cancer
Research Team
L
Liang Jin, Doctor of Medicine(M.D.)
L
Lin Wang, Doctor of Medicine(M.D.)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here